DM
CSTL icon

Deerfield Management’s Castle Biosciences CSTL Stock Holding History

Deerfield Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,943
Closed -$483K – 192
2024
Q3 		$483K Sell
16,943
-857,666
-98% -$21.8M 0.01% 293
2024
Q2 		$19M Sell
874,609
-53,408
-6% -$1.19M 0.32% 53
2024
Q1 		$20.6M Sell
928,017
-37,411
-4% -$814K 0.36% 51
2023
Q4 		$20.8M Buy
965,428
+18,808
+2% +$331K 0.38% 48
2023
Q3 		$16M Buy
+946,620
New +$16.6M 0.35% 48
2023
Q2 		– Sell
-272,135
Closed -$6.18M – 103
2023
Q1 		$6.18M Hold
272,135
– – 0.14% 80
2022
Q4 		$6.41M Buy
+272,135
New +$6.31M 0.13% 74
2019
Q4 		– Sell
-92,477
Closed -$1.67M – 83
2019
Q3 		$1.67M Buy
+92,477
New +$2.05M 0.07% 87

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management's CSTL Position: Q4 2024 in Review

Deerfield Management sold out of Castle Biosciences (CSTL) in Q4 2024, closing a stake of 16,943 shares — an estimated $483K sold.

Deerfield Management first reported a position in CSTL in Q3 2019 and held it in 8 quarters. The position peaked at $20.8M in Q4 2023. 197 funds tracked by Wall St. Rank hold CSTL as of Q4 2024.

  • Deerfield Management reported no remaining Castle Biosciences position as of Q4 2024 after selling out during the quarter.
  • Deerfield Management sold 16,943 Castle Biosciences shares in Q4 2024, an estimated $483K.
  • Deerfield Management first reported a position in Castle Biosciences in Q3 2019 and held it in 8 quarters.
  • Deerfield Management's Castle Biosciences position peaked at $20.8M in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.